Placebo-Controlled, Randomized Trial of Ensitrelvir (S-217622) for Viral Persistence and Inflammation in People Experiencing Long COVID (PREVAIL-LC)

Henrich et al., NCT06161688, PREVAIL-LC, NCT06161688, Apr 2026
50th treatment shown to reduce risk in July 2023, now with p = 0.015 from 8 studies.
Lower risk for hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,500+ studies for 210+ treatments. c19early.org
Meta-analysis
RCT 40 long COVID patients in the USA, showing no significant improvement with ensitrelvir.
Important missing comments or errors? Let us know.
Henrich et al., 2 Apr 2026, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT06161688 (history) (PREVAIL-LC).
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0